Publications by authors named "Peter Gute"

Claim this Profile
E
Expanding epidemic of recently acquired HCV in HIV-coinfected patients over a period of 10 years.
Christiana Graf, Lara Fuhrmann, Thomas Lutz, Christoph Stephan, Gaby Knecht, Peter Gute

JHEP Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
Maximilian Donath, Timo Wolf, Martin Stürmer, Eva Herrmann, Markus Bickel, Peter Gute

Med Microbiol Immunol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels.
Georgios Grammatikos, Julia Dietz, Nerea Ferreiros, Alexander Koch, Georg Dultz, Peter Gute

Int J Mol Sci· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection.
Julia Dietz, Thomas Lutz, Gaby Knecht, Peter Gute, Caterina Berkowski

Virology· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
Ingeborg B Fraunholz, Annette Haberl, Stephan Klauke, Peter Gute, Claus M Rödel

Dis Colon Rectum· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.
Christoph Stephan, Valentin Bartha, Eva Herrmann, Nils von Hentig, Pavel Khaykin, Peter Gute

Med Microbiol Immunol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.
Johannes Vermehren, Annika Vermehren, Axel Mueller, Amina Carlebach, Thomas Lutz, Peter Gute

BMC Gastroenterol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.
Martin Stürmer, Christoph Stephan, Peter Gute, Gaby Knecht, Markus Bickel

Antimicrob Agents Chemother· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Christoph Stephan, Brenda Dauer, Pavel Khaykin, Martin Stuermer, Peter Gute

Curr HIV Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors.
Nils von Hentig, Ann-Kristin Förster, Karina Kuczka, Ute Klinkhardt, Stefan Klauke, Peter Gute

J Antimicrob Chemother· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is transmission of HIV-1 in non-viraemic serodiscordant couples possible?
Martin Stürmer, Hans W Doerr, Annemarie Berger, Peter Gute

Antivir Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo.
Jochen Graff, Nils von Hentig, Karina Kuczka, Carlo Angioni, Peter Gute

J Antimicrob Chemother· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Schlomo Staszewski, Errol Babacan, Christoph Stephan, Annette Haberl, Amina Carlebach, Peter Gute

J Antimicrob Chemother· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
Nils von Hentig, Amina Carlebach, Peter Gute, Gaby Knecht, Stefan Klauke

Br J Clin Pharmacol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to 'Single phylogenetic reconstruction method is insufficient to clarify relationships between patient isolates in HIV-1 transmission case' by Jenwitheesuk and Liu.
Martin Stürmer, Wolfgang Preiser, Peter Gute, Gaby Nisius, Hans W Doerr

AIDS· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phylogenetic analysis of HIV-1 transmission: pol gene sequences are insufficient to clarify true relationships between patient isolates.
Martin Stürmer, Wolfgang Preiser, Peter Gute, Gaby Nisius, Hans W Doerr

AIDS· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals.
Colette J Smith, Schlomo Staszewski, Caroline A Sabin, Mark Nelson, Brenda Dauer, Peter Gute

J Acquir Immune Defic Syndr· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis